Posted on

cbd oil and memory

Cannabis, CBD oil and dementia

Currently there is no evidence to show that cannabis or cannabis oil (CBD oil) can stop, reverse or prevent dementia.

Can cannabis or CBD oil treat dementia or its symptoms?

There are no research studies that prove cannabis, or products such as cannabis oil (CBD oil), can stop, slow, reverse or prevent the diseases that cause dementia.

Some studies suggest cannabis could help to manage a few behavioural symptoms of dementia, such as agitation and aggression.

But more research is needed to understand the long-term effects of taking cannabis, and whether it is an effective and safe way to tackle dementia symptoms.

If you have any questions or concerns about cannabis use and the risk of dementia or other brain disorders, please talk to your GP.

Read our advice to help reduce your risk of developing dementia.

What is cannabis?

Coconut oil and dementia

Cannabis, also known as marijuana, is a plant. The dried leaves, flowering parts or resin extracted from the plant is taken recreationally.

Cannabis is made up for two main components – Tetrahydrocannabinol and Cannabidiol.

What is Tetrahydrocannabinol (THC)?

THC is the main component of cannabis that invokes feelings of sociability, happiness or relaxation.

Products containing more than 0.2% THC are not legally available in the UK.

What is Cannabidiol (CBD)?

Cannabidiol or CBD does not cause any psychoactive or intoxicating effects.

Products that contain CBD are legal and can be bought on the high street or online.

Is there any evidence behind the cannabis and CBD oil claims?

There have been no clinical trials on the effects of cannabis or CBD oil in people living with dementia.

In the lab

A key hallmark of Alzheimer’s disease is the build up of clumps of a protein, called amyloid, in the brain. Some studies have shown that components of cannabis, including THC, appear to remove this protein from nerve cells grown in the lab.

Another study that gave both THC and CBD oil to mice with symptoms of Alzheimer’s disease showed an improved in learning and had less evidence of amyloid clumps in their bodies.

Research continues to better understand the effects of CBD oil on the brain. Some early evidence suggests that CBD oil may reduce inflammation in the brain, although this has yet to be proven in people.

The truth about clinical trials: 5 big myth busters

Dementia researchers Jason and Harri from UCL

Tackling the symptoms of dementia

Research does suggest that high concentrations of CBD oil could be useful for managing some of the symptoms of dementia such as agitation and anxiety.

A few small clinical trials have assessed the effects of cannabinoids (including THC and synthetic cannabinoids, such as nabilone) on behavioural symptoms of dementia. However, trials and studies so far have generally been small or low quality making it difficult to come to a conclusion.

It is also important to note that the researchers in these studies have used high concentrations of CBD oil that may not be available to buy. These studies have also been short term so we still don’t know what the long term effects of using CBD oil might be.

A study is currently underway at King’s College London that will look at whether a mouth spray containing cannabinoids could be used to reduce symptoms of agitation and aggression in a small group of people with Alzheimer’s disease.

Treating and preventing dementia

The jury is still out on whether cannabis or its by-products could be used to treat dementia. A lack of strong research studies mean that dubious and anecdotal reports have taken the place of hard evidence.

No studies or trials have looked into the effects of cannabis or its components on the underlying causes of Alzheimer’s disease in people.

Whilst the studies in the laboratory show some promise, we need to understand the wider effects that these components have before we can know whether they have any effect – positive or negative – on the development of Alzheimer’s in people.

There is some evidence that heavy, long-term use of cannabis could have a negative effect on our memory and thinking. Much more research needs to be done to tease apart any potential benefits and drawbacks.

It is also worth noting that many of these studies have involved a particular component of cannabis in isolation. Even if one component is found to influence dementia risk, it doesn’t necessarily mean that taking cannabis would have the same effect.

There is also a large amount of variation in the levels of THC and CBD oil in different strains of the plant so the effects could depend on the type of cannabis used.

Has Alzheimer’s Society ever funded research into cannabis and dementia?

Alzheimer’s Society has never funded research into cannabis and dementia risk, or into cannabis as a potential treatment for dementia symptoms.

This is because we have not received any high-quality applications from researchers intending to investigate these issues.

If we received a high-quality application into cannabis and dementia from a researcher based at a UK university, research institute or NHS trust, then we would certainly consider this for funding.

Currently there is no evidence to show that cannabis or cannabis oil (CBD oil) can stop, reverse or prevent dementia.

Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study: naturalistic study [corrected]

Affiliation

  • 1 Clinical Psychopharmacology Unit, University College London, Gower St, London WC1E 6BT, UK.
  • PMID: 20884951
  • DOI: 10.1192/bjp.bp.110.077503

Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study: naturalistic study [corrected]

  • Search in PubMed
  • Search in NLM Catalog
  • Add to Search

Authors

Affiliation

  • 1 Clinical Psychopharmacology Unit, University College London, Gower St, London WC1E 6BT, UK.
  • PMID: 20884951
  • DOI: 10.1192/bjp.bp.110.077503

Erratum in

  • Br J Psychiatry. 2010 Nov;197:416

Abstract

Background: The two main constituents of cannabis, cannabidiol and Δ(9)-tetrahydrocannabinol (THC), have opposing effects both pharmacologically and behaviourally when administered in the laboratory. Street cannabis is known to contain varying levels of each cannabinoid.

Aims: To study how the varying levels of cannabidiol and THC have an impact on the acute effects of the drug in naturalistic settings.

Method: Cannabis users (n = 134) were tested 7 days apart on measures of memory and psychotomimetic symptoms, once while they were drug free and once while acutely intoxicated by their own chosen smoked cannabis. Using an unprecedented methodology, a sample of cannabis (as well as saliva) was collected from each user and analysed for levels of cannabinoids. On the basis of highest and lowest cannabidiol content of cannabis, two groups of individuals were directly compared.

Results: Groups did not differ in the THC content of the cannabis they smoked. Unlike the marked impairment in prose recall of individuals who smoked cannabis low in cannabidiol, participants smoking cannabis high in cannabidiol showed no memory impairment. Cannabidiol content did not affect psychotomimetic symptoms, which were elevated in both groups when intoxicated.

Conclusions: The antagonistic effects of cannabidiol at the CB(1) receptor are probably responsible for its profile in smoked cannabis, attenuating the memory-impairing effects of THC. In terms of harm reduction, users should be made aware of the higher risk of memory impairment associated with smoking low-cannabidiol strains of cannabis like ‘skunk’ and encouraged to use strains containing higher levels of cannabidiol.

The antagonistic effects of cannabidiol at the CB(1) receptor are probably responsible for its profile in smoked cannabis, attenuating the memory-impairing effects of THC. In terms of harm reduction, users should be made aware of the higher risk of memory impairment associated with smoking low-canna …